Kuros Biosciences (CSBTF) Ratios
Kuros Biosciences Ratios
CSBTF's free cash flow for Q2 2026 was $-7.53M. For the 2026 fiscal year, CSBTF's free cash flow was decreased by $-5.29M and operating cash flow was $-2.24M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.96 | 2.14 | 2.06 | 2.49 | 2.91 |
| Quick Ratio | 1.45 | 1.69 | 1.69 | 2.24 | 2.76 |
| Cash Ratio | 0.47 | 0.84 | 1.08 | 1.91 | 2.54 |
| Solvency Ratio | 0.12 | -0.04 | -0.74 | -0.83 | -0.32 |
| Operating Cash Flow Ratio | -0.01 | 0.15 | -0.67 | -0.58 | -0.48 |
| Short-Term Operating Cash Flow Coverage | -0.73 | 5.94 | -15.30 | -1.18 | -0.80 |
| Net Current Asset Value | $ 25.21M | $ 18.96M | $ 12.44M | $ 17.31M | $ 18.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.02 | 0.03 | 0.02 | 0.10 |
| Debt-to-Equity Ratio | 0.06 | 0.03 | 0.04 | 0.03 | 0.12 |
| Debt-to-Capital Ratio | 0.06 | 0.03 | 0.04 | 0.03 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.05 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.60 | 1.44 | 1.26 | 1.20 | 1.19 |
| Debt Service Coverage Ratio | 9.59 | -1.37 | -9.45 | -0.71 | -0.40 |
| Interest Coverage Ratio | 24.04 | -33.52 | -70.92 | -3.11 | -6.34 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.12 | 0.11 |
| Interest Debt Per Share | 0.11 | 0.05 | 0.06 | 0.18 | 0.31 |
| Net Debt to EBITDA | -1.17 | 27.93 | 1.76 | 2.51 | 3.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 86.39% | 82.10% | 71.31% | 59.87% | 72.86% |
| EBIT Margin | 6.04% | -4.23% | -28.57% | -64.91% | -59.15% |
| EBITDA Margin | 8.25% | -0.74% | -20.37% | -49.15% | -38.30% |
| Operating Profit Margin | 6.04% | -6.61% | -39.30% | -74.76% | -63.46% |
| Pretax Profit Margin | 3.43% | -4.43% | -29.13% | -88.91% | -69.16% |
| Net Profit Margin | 1.75% | -4.92% | -40.90% | -81.15% | -54.59% |
| Continuous Operations Profit Margin | 1.69% | -4.92% | -30.26% | -81.15% | -54.59% |
| Net Income Per EBT | 50.87% | 111.06% | 140.42% | 91.27% | 78.93% |
| EBT Per EBIT | 56.84% | 66.99% | 74.11% | 118.93% | 108.98% |
| Return on Assets (ROA) | 1.98% | -4.40% | -19.21% | -17.60% | -8.26% |
| Return on Equity (ROE) | 3.17% | -6.33% | -24.20% | -21.20% | -9.80% |
| Return on Capital Employed (ROCE) | 9.93% | -7.85% | -22.64% | -19.11% | -10.95% |
| Return on Invested Capital (ROIC) | 4.80% | -7.72% | -22.20% | -15.94% | -7.94% |
| Return on Tangible Assets | 2.83% | -7.42% | -45.03% | -42.65% | -21.34% |
| Earnings Yield | 0.20% | -0.47% | -10.75% | -29.29% | -11.95% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.81 | 5.06 | 4.41 | 4.97 | 7.36 |
| Payables Turnover | 1.51 | 1.96 | 7.40 | 5.54 | 4.43 |
| Inventory Turnover | 0.98 | 1.43 | 1.98 | 2.28 | 2.13 |
| Fixed Asset Turnover | 32.72 | 24.99 | 12.70 | 7.74 | 5.65 |
| Asset Turnover | 1.13 | 0.89 | 0.47 | 0.22 | 0.15 |
| Working Capital Turnover Ratio | 4.34 | 3.99 | 2.05 | 0.89 | 0.53 |
| Cash Conversion Cycle | 227.99 | 140.44 | 217.60 | 167.90 | 138.26 |
| Days of Sales Outstanding | 95.83 | 72.14 | 82.83 | 73.42 | 49.56 |
| Days of Inventory Outstanding | 374.11 | 254.86 | 184.09 | 160.32 | 171.06 |
| Days of Payables Outstanding | 241.94 | 186.55 | 49.32 | 65.85 | 82.37 |
| Operating Cycle | 469.93 | 326.99 | 266.93 | 233.74 | 220.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | 0.08 | -0.24 | -0.22 | -0.17 |
| Free Cash Flow Per Share | -0.06 | 0.05 | -0.25 | -0.23 | -0.18 |
| Dividend Paid and CapEx Coverage Ratio | -0.19 | 2.82 | -27.13 | -18.37 | -14.58 |
| Capital Expenditure Coverage Ratio | -0.19 | 2.82 | -27.13 | -18.37 | -14.58 |
| Operating Cash Flow Coverage Ratio | -0.10 | 1.75 | -4.13 | -3.84 | -0.61 |
| Operating Cash Flow to Sales Ratio | -0.00 | 0.04 | -0.26 | -0.41 | -0.39 |
| Free Cash Flow Yield | -0.23% | 0.26% | -7.18% | -15.55% | -9.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 498.73 | -213.71 | -9.30 | -3.41 | -8.37 |
| Price-to-Sales (P/S) Ratio | 8.71 | 10.51 | 3.80 | 2.77 | 4.57 |
| Price-to-Book (P/B) Ratio | 15.78 | 13.52 | 2.25 | 0.72 | 0.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -439.50 | 391.61 | -13.92 | -6.43 | -10.83 |
| Price-to-Operating Cash Flow Ratio | -2795.41 | 252.93 | -14.44 | -6.78 | -11.58 |
| Price-to-Earnings Growth (PEG) Ratio | -3.21 | 2.90 | 0.80 | -0.04 | 0.16 |
| Enterprise Value Multiple | 104.39 | -1387.74 | -16.91 | -3.13 | -8.21 |
| Enterprise Value | 1.04B | 778.52M | 115.61M | 27.68M | 43.43M |
| EV to EBITDA | 104.39 | -1387.74 | -16.91 | -3.13 | -8.21 |
| EV to Sales | 8.61 | 10.30 | 3.44 | 1.54 | 3.14 |
| EV to Free Cash Flow | -434.62 | 383.89 | -12.61 | -3.57 | -7.45 |
| EV to Operating Cash Flow | -2764.38 | 247.94 | -13.07 | -3.77 | -7.96 |
| Tangible Book Value Per Share | 0.90 | 0.65 | 0.43 | 0.59 | 0.64 |
| Shareholders’ Equity Per Share | 1.74 | 1.58 | 1.55 | 2.03 | 2.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.51 | -0.11 | -0.04 | 0.09 | 0.21 |
| Revenue Per Share | 3.16 | 2.03 | 0.92 | 0.53 | 0.42 |
| Net Income Per Share | 0.06 | -0.10 | -0.38 | -0.43 | -0.23 |
| Tax Burden | 0.51 | 1.11 | 1.40 | 0.91 | 0.79 |
| Interest Burden | 0.57 | 1.05 | 1.02 | 1.37 | 1.17 |
| Research & Development to Revenue | 0.07 | 0.09 | 0.06 | 0.29 | 0.36 |
| SG&A to Revenue | 0.67 | 0.55 | 0.25 | 0.17 | 0.19 |
| Stock-Based Compensation to Revenue | 0.03 | 0.07 | 0.03 | 0.06 | 0.03 |
| Income Quality | -0.07 | -0.80 | 0.64 | 0.46 | 0.57 |
Currency in CHF